[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prevention\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prevention":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,46,0,25,[9,48,74,99,127,153,189,217,246,274,305,333,360,386,412,439,470,492,515,545,574,594,614,660,685],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100054257","early-test-of-an-innovative-child-maltreatment-cm-prevention-strategy-100054257",false,"NCT06912685","Early Test of an Innovative Child Maltreatment (CM) Prevention Strategy","Pilot Test of an Innovative Implementation Strategy to Improve Reach, Quality, and Equity in Child Maltreatment Prevention","(CM)","Inclusion Criteria:\n\n* At least 18 years old\n* English language proficiency\n* Ability to provide informed consent for themselves\n* Has at least one child between the ages of 0-5 years old - Caregivers Only\n* Has completed at least 1 module of SafeCare since April 2021 - Caregivers Only\n* SafeCare enrollment has been completed (e.g., not currently enrolled in SafeCare). - Caregivers Only\n* Current employment at a SafeCare agency - Agency Leaders Only\n* Full- or part-time employment at a SafeCare agency - Providers Only\n* Must be fully certified to provide SafeCare services - Providers Only\n* Must be providing services for at least 6 months - Providers Only\n\nExclusion Criteria:\n\n* Evidence of significant cognitive disability, developmental delay, or pervasive developmental disorder that would prohibit capacity to consent for themselves - Caregivers Only\n* There are no primary exclusion criteria for the Providers.\n* There are no primary exclusion criteria for Agency Leaders.",true,"ALL","18 Years",{"count":22,"type":23},62,"ESTIMATED","INTERVENTIONAL",[26],"NA","Millions of children are victims of maltreatment each year in the United States. Research on home visiting programs show that child maltreatment can be prevented; however, these programs struggle to reach families in need and provide high quality care. SafeCare is a sustainable and effective home visiting child maltreatment prevention program, serving over 8,000 families each year. This study will examine the feasibility and implementation of a hybrid in-person\u002Fvirtual delivery model for SafeCare with 12 home visiting providers and 40 caregivers to inform how home visiting programs are delivered to maximize reach to families, improve family outcomes, and decrease harm to children.",[29,30,31],"Parenting Intervention","Maltreatment","Prevention",[33,34,35],"Disease Prevention","Healthy Volunteer Studies","Infant","NOT_YET_RECRUITING","2026-07-10",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":23},"2027-01-01",{"date":44,"type":23},"2028-01-01",{"name":46,"class":47},"Medical University of South Carolina","OTHER",{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":24,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100625076","hybrid-delivery-to-increase-access-and-sustainability-evaluating-ezparent-implementation-100625076","NCT07417930","Hybrid Delivery to Increase Access and Sustainability: Evaluating ezParent Implementation","ezParent FT","Inclusion Criteria:\n\n* Parent or legal guardian of a 2-5-year-old child receiving services at the partnering organization site.\n* Speaks English or Spanish.\n* Has a smartphone, tablet, or computer with Wi-Fi access to receive the ezParent program.\n\nExclusion Criteria:\n\n• Parents who have previously participated in CPP or ezParent will be excluded.",{"count":56,"type":23},516,[26],"The goal of this study is to evaluate the effects of the hybrid ezParent program (e.g., web-based training program plus synchronous group sessions) on parent and child outcomes in a community setting serving parents of children 2-5 years old. Parent participants will complete surveys at baseline, and 10 and 24-weeks post baseline.",[60,31,61,62],"Parenting","Program Implementation","Early Childhood","2026-06-29",{"date":65,"type":40},"2026-07-01",{"date":67,"type":23},"2026-08-01",{"date":69,"type":23},"2028-09-30",{"name":71,"class":72},"Klein Buendel, Inc.","INDUSTRY",1,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":24,"phases":83,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":73},"100644783","substance-use-prevention-for-recently-displaced-adults---supra-r33-rct-100644783","NCT07672457","Substance Use Prevention for Recently Displaced Adults - SUPRA (R33) RCT","SUPRA RCT R33","Inclusion Criteria:\n\n1. Age 18 or over\n2. Have been displaced at least once due to Anti-Terrorist Operation (ATO) or full-scale invasion since 2014\n3. Self-reported use of at least one substance other than alcohol and tobacco within the past 3 months\n4. Ability to provide informed consent and speak Ukrainian or Russian\n\nExclusion Criteria:\n\n1. Self-reported diagnosis of a substance use disorder\n2. Inability to provide informed consent",{"count":82,"type":23},144,[26],"This study is a randomized controlled trial among 144 internally displaced people to determine the feasibility, acceptability, and preliminary effectiveness of a single-session Acceptance of Commitment Therapy (ACT) group therapy on preventing or reducing substance use behaviors.",[31,86,87],"Substance Use","Refugee Health",[89,90,86],"Displacement","Ukraine","2026-06-23",{"date":63,"type":40},{"date":94,"type":23},"2027-04",{"date":96,"type":23},"2028-12",{"name":98,"class":47},"Boston Medical Center",{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":106,"minAge":20,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":24,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":73},"100632269","ondansetron-lozenge-versus-intravenous-for-prevention-of-shivering-in-cesarean-section-100632269","NCT07511491","Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section","Effect of Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age from 18 to 40 years.\n* American Society of Anesthesiology (ASA) physical status II.\n* Parturient women undergoing cesarean section under spinal anesthesia.\n\nExclusion Criteria:\n\n* Parturient women with any contraindication or hypersensitivity to the study drugs.\n* Any history of cardiovascular diseases, psychosis, hypertension, fetal distress, cord prolapse initial.\n* Preoperative shivering.\n* Preoperative fever (\\>38°C).\n* Body mass index \\> 40 kg\u002Fm2.\n* Medical history of alcohol or drug abuse.\n* Hypo- or hyperthyroidism.\n* Parkinson's disease or any extrapyramidal disease.\n* Intraoperative blood transfusion.","FEMALE","40 Years",{"count":109,"type":23},90,[26],"This study aims to compare the effect of ondansetron lozenge and intravenous for prevention of shivering in cesarean section (CS).",[113,114,115,31,116,117],"Ondansetron","Lozenge","Intravenous","Shivering","Cesarean Section","RECRUITING","2026-06-22",{"date":91,"type":40},{"date":122,"type":40},"2026-04-11",{"date":124,"type":23},"2026-08-30",{"name":126,"class":47},"Tanta University",{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":19,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":24,"phases":137,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":73},"100616427","enhancing-an-existing-prevention-strategy-to-reduce-intentional-firearm-injuries-among-high-risk-youth-phase-1-100616427","NCT07305467","Enhancing an Existing Prevention Strategy to Reduce Intentional Firearm Injuries Among High-risk Youth (Phase 1)","Inclusion Criteria:\n\n* Youth aged approximately 13-17 years.\n* Identified as at elevated risk for firearm-related injury (e.g., history of violent injury, referred by violence prevention programs).\n* Able to provide assent (and parental\u002Fguardian consent if under 18).\n* Sufficient proficiency in English to complete study procedures.\n\nExclusion Criteria:\n\n* Significant cognitive impairment or developmental disability that would preclude comprehension of the intervention content or study procedures.\n* Current psychiatric or medical instability requiring immediate treatment or hospitalization. - Non-English speaking (due to limited resources for translation of study measures and intervention materials in this pilot).","13 Years","17 Years",{"count":136,"type":23},45,[26],"Over the past three decades, substantial resources have been devoted to developing youth violence prevention (YVP) programs. These programs have demonstrated positive effects on reducing aggression and related behaviors, firearm-specific risk factors were largely overlooked due to historical barriers to firearm research. This omission is concerning, as firearms are now the leading cause of injury and death among U.S. youth. Existing YVP strategies such as Emerging Leaders address general violence risk but do not directly target firearm-related risks or suicide prevention. There remains a critical gap in prevention strategies that integrate firearm-specific content while leveraging established program infrastructure.",[31],[141,142,143],"Firearm injury prevention","community based programs","youth advisory board","2026-06-08",{"date":146,"type":40},"2026-06-09",{"date":148,"type":23},"2026-07",{"date":150,"type":23},"2027-01",{"name":152,"class":47},"Virginia Commonwealth University",{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":18,"sex":159,"minAge":20,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":24,"phases":163,"briefSummary":164,"conditions":165,"keywords":172,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":73},"100638291","effects-of-carbon-fiber-insoles-on-cmj-and-sprint-performance-100638291","NCT07589231","Effects of Carbon Fiber Insoles on CMJ and Sprint Performance","Inclusion Criteria:\n\n* Men aged 18-30 years\n* Moderate physical activity (2-4 times\u002Fweek)\n* No injuries in the last 6 months\n\nExclusion Criteria:\n\n* Use of orthoses or podiatric pathologies\n* Neurological or cardiovascular disease\n* Refusal to sign informed consent","MALE","30 Years",{"count":162,"type":23},38,[26],"This study evaluates the effects of VKTRY carbon fiber insoles on vertical jump and sprint performance in moderately active men. Participants will perform tests with and without insoles, assessing both objective performance and subjective perception using a Likert-type scale.",[166,167,31,168,169,170,171],"Healthy","Sportsman","Performance","Healthy Adult Man","Sports Performance","Athletic Performance and Injury Risk",[173,174,175,176,177,178,179],"sprint","insoles","carbon fiber insoles","vertical jump","biomechanics","sports performance","my jump lab","2026-05-13",{"date":182,"type":40},"2026-05-15",{"date":184,"type":40},"2025-10-30",{"date":186,"type":23},"2026-06-30",{"name":188,"class":47},"Benjamín Cuenca Valero",{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":19,"minAge":195,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":24,"phases":198,"briefSummary":199,"conditions":200,"keywords":203,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":216},"100634523","evaluation-of-7-day-vs-1-day-packaging-of-small-quantity-lipid-based-nutrition-supplementation-sq-lns-100634523","NCT07540793","Evaluation of 7-day vs 1-day Packaging of Small Quantity Lipid-based Nutrition Supplementation (SQ-LNS)","Inclusion Criteria (must meet all):\n\n* Written informed consent from head of household\n* Household within the study area\n* Available for the full 8-week study period\n* 1 child aged 6-22 months in the household at time of enrollment\n* Child has MUAC ≥ 12.5cm\n* Child does not have any clinical complications requiring inpatient treatment or referral to the health post, according to Ethiopian malnutrition treatment guidelines\\*\\*\n* Child is not allergic to peanuts, milk, or soy\n* Household does not have multiple children within the eligible age range\n\nExclusion Criteria (any excludes):\n\n* Head of household declines to sign written informed consent\n* Household is outside of the study area\n* Not available for the full 8-week study period\n* House has either multiple children aged 6-22 months in the household at time of enrollment, or 0 children aged 6-22 months at time of enrollment\n* Child has MUAC \\\u003C 12.5cm\n* Child has any clinical complications requiring inpatient treatment or referral to the health post, according to Ethiopian malnutrition treatment guidelines\n* Child is allergic to peanuts, milk, or soy","6 Months",{"count":197,"type":23},100,[26],"Small Quantity Lipid-based Nutrient Supplements (SQ-LNS), are fortified, lipid-based nutritional supplements that were specifically designed for children 6-24 months to prevent malnutrition. Recent research has shown reductions in mortality, severe wasting, severe stunting, iron deficiency anemia, and developmental delays.\n\nSQ-LNS is currently available in individual daily dose packets of 20g. Healthy children age 6-24 months receive 1 packet per day (1dp), and are typically given a 1- or 2- month supply at a time (30-60 packets).\n\nRecently, Nutriset Développement has developed a new packaging design for SQ-LNS that reduces the cost by over 15% overall, through production efficiency with 40% less packaging, and improved transportation efficiency by 20%. This new packaging is a 140g packet that will allow 20g to be dispensed daily for 7 days (7dp). The packaging has a chamber that will allow for accurate 10g dosing (either twice daily, or twice at once). Users of the packaging will also be able to close the spout to minimize risk of microbiological contamination.\n\nEdesia Nutrition is working with Nutriset to conduct field testing of this new packaging for SQ-LNS, and this mixed-methods study in North Shoa Zone, Amhara Region, Ethiopia, will help inform recommendations for the future use of the package. The study seeks to determine (1) the acceptability of integrating SQ-LNS distribution into the malnutrition program; (2) whether adherence to the 2 different package types differs, and if there are differences in usage; (3) and how the packages perform over time, their perceived safety and functionality, and how they are stored.\n\nEducational and communication tools will be developed and pre-tested as part of this study, and will become part of the final deliverable package to Edesia Nutrition, in addition to final recommendations on the product packaging, findings about how the packages are used, and behavior change and nutrition education strategies.\n\nThe primary outcome of the quantitative evaluation will be adherence, calculated as the number of delivered doses of SQ-LNS divided by the number of expected doses per week (7).\n\nAdherence will be measured via weekly self-report via caregiver interview and counts of return of used and unused packages during weekly home visits. The percentage of children who receive a dose during structured observation periods will be calculated. Each adherence outcome will be analyzed separately.",[31,201,202],"Malnutrition, Child","Nutrition",[204,205,206],"Small Quantity Lipid-based Nutrient Supplement","Child nutrition","Malnutrition prevention","2026-05-11",{"date":209,"type":40},"2026-05-14",{"date":211,"type":23},"2026-05",{"date":213,"type":23},"2026-12",{"name":215,"class":47},"University of California, San Francisco",3,{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":24,"phases":226,"briefSummary":227,"conditions":228,"keywords":234,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":73},"100568535","enhancing-oral-cancer-awareness-100568535","NCT06682494","Enhancing Oral Cancer Awareness","Comparative Study on Enhancing Oral Cancer Awareness: Classical Educational Materials vs. AI-Powered Chatbot","Inclusion Criteria:\n\n* Identify as African American as defined by the US Census\n* Participants must be able to read, speak, and write in English\n\nExclusion Criteria:\n\n* Individuals who cannot physically or mentally participate in the research project will be excluded\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners",{"count":225,"type":23},60,[26],"To evaluate the impact of AI-powered chatbot interactions versus traditional educational handouts on increasing participants' knowledge of oral cancer and its prevention",[229,230,231,31,232,233],"Oral Cancer","Chatbot","Patient Education","Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer","Oropharyngeal Cancers",[235,236,237],"AI-powered Chatbox","Oral cancer prevention","Socio-economic barriers","2026-05-07",{"date":240,"type":40},"2026-05-08",{"date":242,"type":40},"2025-09-24",{"date":244,"type":23},"2027-10-31",{"name":152,"class":47},{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":18,"sex":106,"minAge":20,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":24,"phases":255,"briefSummary":256,"conditions":257,"keywords":261,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":73},"100639722","effectiveness-of-an-ai-enabled-mobile-intervention-on-lifestyle-behaviors-and-maternal-infant-health-100639722","NCT07582068","Effectiveness of an AI-Enabled Mobile Intervention on Lifestyle Behaviors and Maternal-Infant Health","Effects of an AI-driven Mobile Health Management Intervention to Prevent Gestational Diabetes Mellitus in High-risk Pregnant Women: A Pragmatic Randomized Controlled Trial","Inclusion Criteria:\n\n* Pregnant women aged ≥18 years\n* Singleton pregnancy\n* Gestational age \\\u003C13+6 weeks at enrollment\n* At least one of the following GDM risk factors:\n\n  1. Age ≥35 years\n  2. Pre-pregnancy BMI ≥24 kg\u002Fm²\n  3. Family history of diabetes (first-degree relatives)\n  4. Previous history of gestational diabetes mellitus\n  5. Prior delivery of a macrosomic infant (birth weight ≥4000 g)\n* Polycystic ovary syndrome\n* Use of an Android smartphone\n* No severe heart, liver, or kidney diseases\n* Voluntary participation and signed informed consent\n\nExclusion Criteria:\n\n* Pre-pregnancy diagnosis of diabetes mellitus (type 1 or type 2)\n* Severe mental illness\n* Confirmed severe pregnancy complications (e.g., preeclampsia, placental abruption, etc.)\n* Inability to complete questionnaires or intervention\n* Participation in other interventional studies",{"count":254,"type":23},400,[26],"The goal of this pragmatic randomized controlled trial is to evaluate the effectiveness of an AI-enabled mobile health management application (\"Better Pregnancy\" app), grounded in the Theory of Planned Behavior, in preventing gestational diabetes mellitus (GDM) among pregnant women at high risk of GDM, and to assess its impact on maternal and infant health outcomes.\n\nStudy Population: Eligible participants are pregnant women aged 18-49 years, with a singleton pregnancy, gestational age \\\u003C12 weeks at enrollment, and at least one GDM risk factor (age ≥35 years, pre-pregnancy BMI ≥24 kg\u002Fm², family history of diabetes, previous history of GDM, prior delivery of a macrosomic infant \\[birth weight ≥4000 g\\], or polycystic ovary syndrome). Participants must have no heart, liver, or kidney diseases, use an Android smartphone, and provide written informed consent.\n\nThe main questions it aims to answer are:\n\nCan the AI-driven mobile lifestyle intervention reduce the incidence of GDM in high-risk pregnant women?\n\nDoes the intervention improve lifestyle behaviors (diet, physical activity, sleep) and glycemic control (measured by continuous glucose monitoring) in participants?\n\nWhat is the adherence, acceptability, and cost-effectiveness of this intervention in real-world clinical settings?\n\nComparison: Researchers will compare two groups of pregnant women: the intervention group (receiving the AI-enabled \"Better Pregnancy\" app plus routine antenatal care) and the control group (receiving routine antenatal care alone).\n\nParticipants will:\n\nEnroll in the first trimester (\\\u003C12 weeks of gestation) and complete a baseline lifestyle and health status questionnaire\n\nIn the intervention group: watch 7 cognitive-attitudinal videos within the first week, then complete 12 weeks of AI-driven personalized intervention (daily check-ins, receiving tailored recommendations on diet, physical activity, sleep, etc.)\n\nDuring the intervention period, participants in the intervention group will wear a continuous glucose monitoring device for 7 days to assess the impact of the intervention on glycemic fluctuations\n\nComplete the first follow-up lifestyle and health status assessment after the intervention (approximately in the second trimester)\n\nUndergo an oral glucose tolerance test during the second trimester (24-28 weeks)\n\nComplete the second follow-up lifestyle and health status assessment in the third trimester (≥28 weeks)\n\nComplete the third follow-up lifestyle and health status assessment at 42 days postpartum, along with collection of delivery outcomes and infant health information\n\nA subset of participants may voluntarily provide blood and stool samples for mechanistic studies",[258,259,31,260],"Mobile Health Apps","Lifestyle Intervention","Multi-component Based Behavioral Intervention",[31,262,263,264],"Gestational diabetes mellitus","Mobile health","Randomized controlled trial","2026-05-06",{"date":267,"type":40},"2026-05-12",{"date":269,"type":23},"2026-08-10",{"date":271,"type":23},"2027-12-31",{"name":273,"class":47},"Fangbiao Tao",{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":24,"phases":284,"briefSummary":285,"conditions":286,"keywords":291,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":73},"100636878","intraoperative-application-of-cold-atmospheric-plasma-to-prevent-postoperative-wound-complications-in-the-inguinal-region-of-high-risk-patients-with-peripheral-arterial-occlusive-disease-100636878","NCT07571408","Intraoperative Application of Cold Atmospheric Plasma to Prevent Postoperative Wound Complications in the Inguinal Region of High-risk Patients With Peripheral Arterial Occlusive Disease","Prophylactic Application of Cold Atmospheric Plasma to Reduce Postoperative Wound Healing Disorders in the Inguinal Region in High-risk Patients With Peripheral Arterial Occlusive Disease- Intraoperative Application of Cold Atmospheric Plasma in the Inguinal Region","PICPAD","Inclusion Criteria:\n\n* Age \\> 18 years\n* Written informed consent\n* Surgical treatment of peripheral arterial occlusive disease (PAOD) with femoral (inguinal) access\n* High-risk patient for wound healing complications:\n\nWHD (wound healing disorder) score ≥ 4 points:\n\nDiabetes mellitus (2) Immunosuppression\u002Fsteroid therapy (2) End-stage renal disease (2) Reinterventions (2) Peripheral arterial occlusive disease (1) Nicotine abuse (1) Obesity (BMI \\> 30) (1) Age \\> 80 years (1) Duration of surgery \\> 4 h (1) Blood loss \\> 1.5 L (1) Local radiotherapy\u002Fchemotherapy (1)\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Femoral access for an indication other than PAOD\n* Preoperative local infection or infectious skin disease\n* Life expectancy \\\u003C 3 months\n* Active infection of the ipsilateral extremity requiring systemic antibiotic therapy at the time of surgery\n* Systemic antibiotic therapy at the time of surgery\n* Use of coated incisional drapes (e.g., iodine-impregnated)\n* Intraoperative use of anti-infective topical agents (e.g., Gentacoll, doxycycline, etc.)\n* Use of fibrin sealants\u002Fthrombogenic adhesive substances above the fascia Planned postoperative prophylactic negative pressure wound therapy (NPWT)",{"count":283,"type":23},214,[26],"The goal of this clinical trial is to learn if postoperative wound complications in the inguinal region of high-risk patients with peripheral arterial occlusive disease can be prevented by the intraoperative application of cold atmospheric plasma.\n\nThe main questions it aims to answer are:\n\nDoes the intraoperative application of cold atmospheric plasma reduce the need for surgical revision of inguinal wounds due to wound healing complications within 3 months postoperatively? Does the intraoperative application of cold atmospheric plasma reduce wound healing complications not requiring revision within 3 months postoperatively?\n\nResearchers will compare the application of cold atmospheric plasma to a placebo (a deactivated look-alike device).\n\nParticipants will:\n\nUndergo surgical treatment with femoral artery access due to their peripheral arterial occlusive disease, in accordance with the respective vascular surgery department standard of care.\n\nReceive a single application of cold atmospheric plasma or, respectively, placebo in the area of their inguinal access wound during surgery (after subcutaneous closure and prior to skin closure).\n\nBe regularly assessed for wound healing during the first postoperative 14 days as part of routine clinical care and undergo a final evaluation at 3 months. They will also be surveyed regarding their quality of life.",[287,288,289,290,31],"Peripheral Occlusive Disease","Wound Healing","Wound Healing Complication","Cold Atmospheric Plasma",[292,293,294,295,296],"cold atmospheric plasma","prevention","wound healing disorder","vascular surgery","peripheral occlusive disease","2026-05-04",{"date":265,"type":40},{"date":300,"type":23},"2026-11-01",{"date":302,"type":23},"2029-06-01",{"name":304,"class":47},"Ursula Werra",{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":18,"sex":19,"minAge":312,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":24,"phases":314,"briefSummary":315,"conditions":316,"keywords":319,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":73},"100586952","the-reminder4care-program-for-older-adults-supported-by-residential-and-daycare-facilities-100586952","NCT06922071","The REMINDER4Care Program for Older Adults Supported by Residential and Daycare Facilities","REMINDER4Care","Inclusion Criteria:\n\n* Aged 65 years and older\n* RDF users\n* Elementary reading and writing skills\n\nExclusion Criteria:\n\n* Have a clinical diagnosis of dementia and\u002For Mini-Mental State Examination (MMSE) scores below the cutoff for the presence of dementia (MMSE \\\u003C 22-27, depending on education level)\n* Have a psychiatric or neurological condition that impairs cognition in the long term\n* Have sensory and functional deficits that compromise their participation in the neuropsychological assessment and throughout the intervention sessions","65 Years",{"count":197,"type":23},[26],"Dementia incidence is rising, posing a public health challenge, but 45% of cases can be prevented by addressing modifiable risk factors. Multidomain trials show that lifestyle changes can improve cognitive function and reduce dementia risk (like the FINGER trial). The REMINDER program, a Portuguese-based dementia risk reduction protocol, was developed for community-dwelling older adults aged 55 and above. However, older adults in Residential and Daycare Facilities (RDF) have distinct needs that demand program adaptation to ensure its relevance and effectiveness. In addition, more studies are needed to evaluate the impact of multidomain interventions with older adults in RDF.\n\nTo address these challenges, the REMINDER4Care program was developed as a tailored, multidomain intervention to reduce dementia risk. It emphasizes social and cognitive engagement and advances its adaptation and evaluation in Residential and Daycare Facilities (RDF). To assess efficacy, the investigators will perform a Randomized Controlled Trial.",[317,31,318],"Dementia Risk Factors","Cognitive Health",[317,31,320,321,322,323],"Health","Aging","Residential and Daycare Facilities","Lifestyle","2026-04-27",{"date":326,"type":40},"2026-05-01",{"date":328,"type":40},"2025-05-01",{"date":330,"type":23},"2026-12-31",{"name":332,"class":47},"University of Coimbra",{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":18,"sex":19,"minAge":339,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":343,"phases":4,"briefSummary":344,"conditions":345,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":4},"100556590","evaluation-of-clinical-decision-support-in-opioid-tapering-100556590","NCT06527079","Evaluation of Clinical Decision Support in Opioid Tapering","Inclusion Criteria: Primary care patients being tapered from an opioid. Tapering patients:\n\n* Have an active opioid prescription for more than 3 months and\n* Prescribed more than 90 morphine milligram equivalents (MME) per day or\n* Co-prescribed an opioid and benzodiazepine or\n* Received a reduction in opioid dosage by more than 5% MME per day\n\nExclusion Criteria:\n\n* Patients \\\u003C12 and \\>89\n* Patients with active cancer diagnosis in last 1 year\n* Patients with hospice care\u002Fpalliative care order\n* Patients with sickle cell disease diagnosis","12 Years","89 Years",{"count":342,"type":23},200000,"OBSERVATIONAL","The 2022 Center for Disease Control and Prevention (CDC) clinical practice guideline for prescribing opioids for pain recommends that when tapering a patient's opioid dose, doses should be decreased at a slow rate to reduce the risk of withdrawal symptoms, overdose, and to promote tolerance of the tapering. This project will evaluate a clinical decision support (CDS) tool in the form of a clinical care pathway that gives providers information, recommendations, and educational material on strategies for opioid tapering. Primary care providers will be randomized at the clinic location to a control arm or intervention arm. The control arm will have the clinical care pathway available, but will not be reminded of the pathway when tapering a patient. The intervention arm will receive a nudge when prescribing a tapering opioid strategy to a patient to use the clinical care pathway. The rate of opioid tapering in line with CDC guidelines will be examined as well as long-term patient outcomes of opioid overdose or poisoning using existing patient health records. The study period will be approximately 18 months.",[346,347,348,349,350,31],"Medication Abuse","Harm Reduction","Opioid Use Disorder","Opioid Prescribing","Opioid Overdose","2026-04-20",{"date":353,"type":40},"2026-04-23",{"date":355,"type":23},"2026-08",{"date":357,"type":23},"2027-06",{"name":359,"class":47},"University of Colorado, Denver",{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":18,"sex":19,"minAge":368,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":24,"phases":371,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":384,"locationsCount":73},"100631273","virtual-assistant-for-exercise-adherence-in-older-adults-100631273","NCT07498530","Virtual Assistant for Exercise Adherence in Older ADULTS","Application of a Virtual Assistant to Enhance Exercise Adherence in Older Adults","AGE-BOT","Inclusion Criteria:\n\n* Adults aged 60 years or older.\n* Community-dwelling individuals capable of participating in an exercise program.\n* Ability to complete 60-minute exercise sessions, three times per week during the 12-week intervention.\n* Experimental group (BOT Group): Participants willing to use a smartphone\u002Ftablet and interact with the virtual assistant.\n* Control group (Municipal Exercise Group): Individuals already enrolled in the municipal program Enguera se saludable.\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Medical contraindications to physical exercise, as determined by clinical judgment (e.g., uncontrolled cardiovascular, respiratory, or metabolic conditions).\n* Severe cognitive impairment or neurological conditions that limit the ability to follow instructions or safely perform the exercise program.\n* Severe mobility limitations preventing participation in structured exercise (e.g., inability to walk independently with or without aid).\n* Acute musculoskeletal injuries or recent surgeries that contraindicate exercise participation.\n* Individuals currently participating in another structured exercise program that would interfere with the study interventions (other than Enguera se saludable for the control group).\n* Inability or unwillingness to comply with the requirements of the study (frequency, duration, assessments).\n* For the BOT group: lack of access to a device compatible with the virtual assistant or inability\u002Funwillingness to use it.","59 Years",{"count":370,"type":23},70,[26],"This study will evaluate the effectiveness of a virtual assistant-guided exercise program to improve adherence in older adults. In a nonrandomized controlled clinical trial, the experimental group will complete a 12-week, home-based program (60-minute sessions, 3 times per week) supported by a virtual assistant (BOT). The control group will comprise community-dwelling older adults already engaged in the municipal program Enguera se saludable, which delivers an in-person exercise program of comparable frequency and duration. The primary outcome is exercise adherence, defined as the proportion of prescribed sessions completed. Secondary outcomes include muscle strength, balance, functional capacity, health-related quality of life, and the user experience and usability of the virtual assistant.",[374,375,376,31,377],"Older Adult","Exercise","Adherence","New Technologies","2026-03-25",{"date":380,"type":40},"2026-03-27",{"date":382,"type":40},"2026-02-01",{"date":330,"type":23},{"name":385,"class":47},"University of Valencia",{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":394,"enrollmentInfo":395,"targetDuration":4,"studyType":24,"phases":397,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":73},"100580876","serial-coronary-cta-based-plaque-progression-detection-for-management-of-coronary-heart-disease-100580876","NCT06843005","Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease","Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease: a Randomised Controlled Trial","SUCCESS","Inclusion Criteria:\n\n1. Age between 18 and 80 years old;\n2. Known patients with non-obstructive coronary artery disease (disease duration ≥2 years);\n3. Patients who agree to undergo follow-up CCTA examinations and cooperate in completing follow-up observations.\n\nExclusion Criteria:\n\n1. Patients who have experienced ACS or PCI\u002FCABG;\n2. Patients who have experienced adverse cardiovascular and cerebrovascular events;\n3. Patients who have undergone follow-up CCTA or DSA examinations before enrollment;\n4. Patients with severe hepatic and renal dysfunction;\n5. Patients with contraindications to CCTA examinations;\n6. Patients with poor initial CCTA image quality or data loss.","80 Years",{"count":396,"type":23},3100,[26],"The primary objective of this study is to evaluate whether a management strategy based on coronary computed tomography angiography (CCTA) for patients with non-obstructive coronary artery disease can improve the LDL-C target achievement rate compared to a traditional management strategy without follow-up CCTA, thereby reducing the incidence of major adverse cardiovascular and cerebrovascular events over a 3 years period, including all-cause mortality, myocardial infarction, ischemia driven revascularation and stroke.",[400,31,401,402],"Major Adverse Cardiovascular Events (MACE)","Coronary Artery Disease(CAD)","CT Angiography","2026-03-19",{"date":405,"type":40},"2026-03-24",{"date":407,"type":40},"2025-02-28",{"date":409,"type":23},"2028-12-30",{"name":411,"class":47},"Zhang longjiang,MD",{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":19,"minAge":419,"maxAge":420,"enrollmentInfo":421,"targetDuration":4,"studyType":24,"phases":423,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":438},"100531339","moxibustion-for-the-prevention-of-hemorrhagic-cystitis-after-allo-hsct-100531339","NCT06198517","Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT","Clinical Study of Moxibustion for the Prevention of Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. Patients are fully aware of the study, participate voluntarily and sign the informed consent form (ICF);\n2. Age: 14-60 years;\n3. Patients with pernicious blood diseases undergoing allo-HSCT using the MAC protocol or patients with severe aplastic anemia (Severe aplastic anemia; severeaplasticanimin, SAA) undergoing allo-HSCT;\n\nExclusion Criteria:\n\n1. refuse to participate in this clinical study;\n2. The corresponding skin at the moxibustion site is broken or sensitive;\n3. allo-HSCT pretreated with the RIC program;","14 Years","60 Years",{"count":422,"type":23},266,[26],"This study was a prospective, multicenter, randomized controlled clinical study planned to recruit 266 hematological patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT), who were randomly divided into two groups according to gender, type of transplantation, and type of primary disease. The control group was treated conventionally, and the experimental group increased moxibustion of Zhongji, Guanyuan and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation. Urine routine tests were performed at the time of admission, +1d, and +14d, and urine BK virus, JC virus, and adenovirus were tested at four time points, namely, +1d, +14 days, onset of hematuria symptoms, and remission of HC, respectively; routine urine tests were performed once every 7 days for all patients within 100days. For patients with Hemorrhagic cystitis (HC), daily severity grading, pain scoring, cystitis symptom scoring, use of antispasmodic and analgesic medications, and major TCM evidence were recorded with the aim of evaluating the efficacy of moxibustion in the prevention of HC in this patient population.",[426,427,428,31],"Moxibustion","Hematopoietic Stem Cell Transplantation","Hemorrhagic Cystitis","2026-03-09",{"date":431,"type":40},"2026-03-12",{"date":433,"type":40},"2024-03-21",{"date":435,"type":23},"2026-09-30",{"name":437,"class":47},"Yi Zhang",4,{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":19,"minAge":339,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":24,"phases":448,"briefSummary":450,"conditions":451,"keywords":454,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":4},"100619189","phase-4-prevention-of-recurrence-of-herpes-simplex-in-autoimmune-rheumatic-diseases-100619189","NCT07341386","Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases","Prevention of Recurrence of Herpes Simplex in Patients With Autoimmune Rheumatic Diseases","PRoHerpARD","Inclusion Criteria\n\n* Eligible participants must be \\>12 years old\n* Any sex\n* Have a confirmed diagnosis of an autoimmune rheumatic disease (ARD) based on internationally accepted classification criteria, including: rheumatoid arthritis (ACR\u002FEULAR 2010), juvenile idiopathic arthritis (ILAR), axial spondyloarthritis (ASAS 2009), psoriatic arthritis (CASPAR 2012), systemic lupus erythematosus (SLICC 2012), systemic sclerosis (ACR 2013), dermatomyositis\u002Fpolymyositis (Bohan \\& Peter), systemic vasculitis (Takayasu arteritis, granulomatosis with polyangiitis, polyarteritis nodosa), primary Sjögren's syndrome (ACR\u002FEULAR 2016), mixed connective tissue disease (Alarcón-Segovia or Kasukawa criteria), chronic recurrent multifocal osteomyelitis (Jansson et al., 2007), sarcoidosis (ATS\u002FERS\u002FWASOG 2020 statement) and behçet's syndrome (International Study Group, 1990).\n* Present serologic evidence of prior HSV infection (complement fixation titer ≥ 1:8)\n* A clinical history of recurrent oral or genital herpes simplex virus infection, defined as at least four episodes in the past 12 months.\n\nExclusion Criteria\n\n-Participants will be excluded if they have a known hypersensitivity to acyclovir or any component of the study medication.",{"count":22,"type":23},[449],"PHASE4","The goal of this randomized, double-blind, placebo-controlled clinical trial is to evaluate the effectiveness and safety of oral suppressive therapy with acyclovir in preventing herpes simplex virus (HSV) reactivation in patients with autoimmune rheumatic diseases (ARDs) who have a history of recurrent HS episodes.\n\nThe main questions this study aims to answer are:\n\nDoes continuous oral acyclovir reduce the frequency of HSV reactivation in ARD patients compared to placebo? What is the safety profile of prolonged acyclovir use in this population? What are the main risk factors (clinical and treatment-related) associated with HSV reactivation in immunosuppressed patients.\n\nParticipants will:\n\nBe randomly assigned (1:1) to receive oral acyclovir (400 mg BID) or placebo for 12 months; Be followed for a total of 24 months, with regular clinical evaluations (every 3 months) and laboratory monitoring (every 3 months); Be assessed for HSV recurrence based on clinical symptoms, detection of HSV DNA by polymerase chain reaction (PCR) in mucocutaneous swabs in doubtful cases, and standardized reporting forms; Undergo disease activity assessments and adverse event monitoring at regular intervals.\n\nThe study includes adult and pediatric patients with confirmed diagnoses of one of the following ARDs: systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), dermatomyositis\u002Fpolymyositis (DM\u002FPM), systemic sclerosis (SSc), systemic vasculitis, primary Sjögren's syndrome, Mixed connective tissue disease (MCTD), Chronic recurrent multifocal osteomyelitis (CRMO), Sarcoidosis and Behçet's Syndrome. All participants must have a documented history of recurrent HSV (oral and\u002For genital) before inclusion.",[452,453,31],"Autoimmune Rheumatic Diseases","Recurrent Herpes Simplex",[455,456,452,457,458,459,460],"Herpes Simplex Virus","Acyclovir","Rheumatology","Pediatric Rheumatology","Antiviral Suppressive Therapy","Infectious Disease Prevention","2026-03-03",{"date":463,"type":40},"2026-03-05",{"date":465,"type":23},"2026-04-01",{"date":467,"type":23},"2028-04-01",{"name":469,"class":47},"University of Sao Paulo General Hospital",{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":24,"phases":478,"briefSummary":480,"conditions":481,"keywords":483,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":488,"completionDateStruct":489,"leadSponsor":490,"locationsCount":73},"100612030","phase-3-adding-aprepitant-to-a-multimodal-strategy-for-the-prevention-of-postoperative-nausea-and-vomiting-in-high-risk-outpatient-surgical-patients-100612030","NCT07248280","Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients","Inclusion Criteria:\n\n* 18 years and over, requiring an ambulatory surgery\n* at high risk of post-operative nausea and vomitting defined by at least 3 factors from the Apfel score, calculated just prior to the surgery (female sex; non smoker; previous nausea or vomitting post-op., or motion sickness; expected opioid consumption in postoperative care).\n\nExclusion Criteria:\n\n* Refusal or unable to consent\n* Suspected or documented allergy to aprepitant (emend)\n* Concomitant use of medication interacting via the cytochrome CYP3A4 with aprepitant (pimozide, terfenadine, astemizole, comtadin or cisapride).",{"count":477,"type":23},260,[479],"PHASE3","Postoperative nausea and vomiting (PONV) are a frequent and debilitating complications after surgery, affecting up to 80% of patients at high risk in the absence of prophylaxis.\n\nDespite the rigorous application of the recommendations from the American Society of Anesthesiologists (ASA) at CHUM, a recent local study reveals a prevalence of 25% PONV at home after outpatient surgery. However, the therapeutic options at home remain limited.\n\nThis study aims to evaluate if the addition of 40 mg aprepitant to a multimodal strategy for preventing PONV improves clinical outcomes in high-risk patients undergoing outpatient surgery.",[482,31],"Nausea and Vomiting, Postoperative",[484,485],"Ambulatory care","Aprepitant","2026-02-27",{"date":461,"type":40},{"date":486,"type":40},{"date":42,"type":23},{"name":491,"class":47},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":106,"minAge":20,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":343,"phases":4,"briefSummary":500,"conditions":501,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":514},"100622358","development-of-a-shared-decision-tool-to-facilitate-uptake-of-the-levonorgestrel-releasing-intrauterine-system-for-the-primary-prevention-of-endometrial-cancer-100622358","NCT07382583","Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer","Inclusion Criteria:\n\n1. Unaffected women\n\n   1. Must be at least 18 years old\n   2. Must read and speak English or Spanish\n   3. Must be premenopausal\n   4. Must not have a prior history of EC or complex atypical hyperplasia\n   5. Must provide written, informed consent\n   6. No physical, psychological, or cognitive impairments that would preclude participation in an interview as determined by the PI or study team member\n2. Affected women\n\n   1. Must be at least 18 years old\n   2. Must read and speak English or Spanish\n   3. Must have a prior history of EC or complex atypical hyperplasia\n   4. Must provide written, informed consent\n   5. No physical, psychological, or cognitive impairments that would preclude participation in an interview as determined by the PI or study team member\n3. Healthcare Providers\n\n   1. Physicians or advanced practice providers (physician assistants, nurse practitioners) from Family Medicine, Obstetrics \\& Gynecology, Internal Medicine, or Endocrinology\n   2. Must be at least 18 years old\n   3. Must read and speak English or Spanish\n   4. Must provide written, informed consent for qualitative interviews\n\nExclusion Criteria:\n\n* N\u002FA",{"count":499,"type":23},270,"To develop an educational tool to help patients and healthcare professionals make informed decisions about endometrial cancer and available prevention options for it (such as the use of a levonorgestrel-releasing intrauterine system \\[LNG-IUS\\]).",[502,503,31,504],"Levonorgestrel","Intrauterine Systems","Endometrial Cancer","2026-02-24",{"date":507,"type":40},"2026-02-25",{"date":509,"type":40},"2026-02-12",{"date":511,"type":23},"2030-02-01",{"name":513,"class":47},"M.D. Anderson Cancer Center",2,{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":24,"phases":524,"briefSummary":525,"conditions":526,"keywords":530,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":73},"100625045","active-pauses-for-musculoskeletal-disorder-prevention-in-workers-100625045","NCT07417527","Active Pauses for Musculoskeletal Disorder Prevention in Workers","Prevention Program for Musculoskeletal Disorders Through Active Pauses for Workers in the Basque Country","Inclusion Criteria:\n\n* Active workers.\n* Aged 18 years or older.\n* Capability to perform vigorous physical exercise.\n\nExclusion Criteria:\n\n* Medical contraindications to physical exercise.\n* Recent surgery.\n* Pregnancy.",{"count":523,"type":23},150,[26],"The goal of this clinical trial is to learn if short exercise breaks at work can prevent muscle and joint pain in workers. The main questions it aims to answer are:\n\nDo strength exercises help workers move better and feel less pain?\n\nAre strength exercises better than stretching exercises for worker health?\n\nResearchers will compare a strength exercise program to a mobility (stretching) program to see which one works better to improve physical health and work ability.\n\nParticipants will:\n\nPerform short exercise breaks (5 minutes) at their workplace every day for 8 weeks.\n\nAttend one supervised session per week to learn the exercises.\n\nComplete simple physical tests (like standing up from a chair) and answer surveys about their health at the start and end of the study.",[527,528,529,31],"Musculoskeletal Disorders (MSDs)","Occupational Diseases","Sedentary Behaviors",[531,532,533,534,535],"Active Pauses","Workplace Exercise","Strength Training","Stretching","Occupational Health","2026-02-17",{"date":538,"type":40},"2026-02-19",{"date":540,"type":40},"2026-01-01",{"date":542,"type":23},"2029-12",{"name":544,"class":47},"University of the Basque Country (UPV\u002FEHU)",{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":18,"sex":19,"minAge":552,"maxAge":553,"enrollmentInfo":554,"targetDuration":4,"studyType":24,"phases":556,"briefSummary":557,"conditions":558,"keywords":560,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":514},"100508704","a-cross-sectional-partnership-to-improve-prevention-and-health-equity-among-african-americans-100508704","NCT05903885","A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans","Using a Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans","Inclusion Criteria:\n\n* Self-identification as Black or African American\n* Between 45 and 75 years old\n* Not up-to-date with colorectal cancer (CRC) screening per guidelines\n* Willingness to provide contact information for follow-up\n* Ability to speak, read, and write English\n* Current residency in Douglas County, NE.\n\nExclusion Criteria:\n\n* History of colorectal cancer (CRC)\n* History of adenomas (precancerous polyps) or inflammatory bowel disease\n* Family history of colorectal cancer (CRC)","45 Years","75 Years",{"count":555,"type":23},1200,[26],"African Americans face racial disparities in colorectal cancer (CRC), with lower screening rates and higher incidence and mortality rates. To address this gap and improve CRC screening rates, investigators aims to recruit a total of 1,200 African American participants aged 45-75 during their visits to the DMV, 4606 N 56th St Ste100, Omaha, for CRC screening. All participants will receive a free Fecal Immunochemical Test (FIT) kit with a prepaid return envelope, a culturally tailored educational brochure, reminder text messages and calls, and post-FIT navigation support for participants with positive results or without family doctor\u002Finsurance. Kits are returned to a designated Nebraska Medicine lab for testing, and test results will be mailed to participants within 14-21 days. Participants will be assigned to one of two groups: the on-site distribution group or the on-site distribution group with social media advertising group. The social media advertising group will additionally be exposed to targeted ads on platforms like Facebook, Instagram, and YouTube to increase awareness and potentially improve participation rates. The study will compare FIT kit return rates, positive screening rates, and completion rates of follow-up colonoscopies after positive FIT results between the two groups.",[559,31],"Colorectal Cancer",[31,561,562,563,564],"Department of motor vehicles","Cross-sectoral partnership","African Americans","Screening","2026-02-06",{"date":567,"type":40},"2026-02-10",{"date":569,"type":40},"2023-10-02",{"date":571,"type":23},"2026-10",{"name":573,"class":47},"University of Nebraska",{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":18,"sex":106,"minAge":20,"maxAge":552,"enrollmentInfo":580,"targetDuration":4,"studyType":24,"phases":582,"briefSummary":583,"conditions":584,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":591,"leadSponsor":592,"locationsCount":4},"100541842","implementation-of-prep-care-among-women-in-family-planning-clinics-100541842","NCT06335121","Implementation of PrEP Care Among Women in Family Planning Clinics","Inclusion Criteria:\n\n* Eligible participants include ciswomen presenting at a PPIL health center with a positive STI test (syphilis, gonorrhea, or chlamydia) and identified in the EHR using STI testing records and new fields for optimizing support of provider PrEP counseling.\n\nExclusion Criteria:\n\n\\- Participants will be excluded if they are not PrEP eligible, have a negative STI test, or are not identified in the EHR.",{"count":581,"type":23},250,[26],"This study will evaluate implementation strategies to address barriers and increase uptake of PrEP among Black cisgender women in Planned Parenthood of Illinois (PPIL) health centers.",[585,586,31],"PrEP Uptake","HIV","2026-01-21",{"date":589,"type":40},"2026-01-22",{"date":213,"type":23},{"date":357,"type":23},{"name":593,"class":47},"Rush University Medical Center",{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":600,"eligibilityCriteria":601,"healthyVolunteers":18,"sex":19,"minAge":552,"maxAge":4,"enrollmentInfo":602,"targetDuration":4,"studyType":343,"phases":4,"briefSummary":604,"conditions":605,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":612,"locationsCount":73},"100621653","glucose-observation-and-wearable-use-for-prevention-100621653","NCT07373418","Glucose Observation and Wearable Use for Prevention","GLOW UP: A Single-Center Observational Study Developing Digital Biomarkers for Prediabetes Screening and Lifestyle Phenotyping","GlowUp","Inclusion Criteria:\n\n* Citizens or residents of Switzerland who are German-speaking (main place of living or employment in Switzerland).\n* Age ≥45 years.\n* BMI ≥25 kg\u002Fm² (overweight or obese).\n* Regular access to a smartphone (iOS or Android) with a data plan.\n* Able to use smartphone applications.\n* Able to walk independently.\n\nExclusion Criteria:\n\n* History of stroke, heart disease, renal failure, cancer, or diabetes (type 1 or type 2).\n* Past vascular bypass surgery or angioplasty.\n* Current or planned use of glucose-lowering medications during the upcoming 4 weeks (e.g., GLP-1 receptor agonists, metformin).\n* Pregnant or breastfeeding.\n* Relevant skin conditions at wearable placement sites (e.g., upper arm).\n* BMI \\\u003C25 kg\u002Fm² confirmed at enrollment.\n* FPG ≥7.0 mmol\u002FL and\u002For HbA1c ≥6.5% (newly identified type 2 diabetes); Individuals who meet type-2 diabetes criteria at enrollment, based on Swiss\u002FADA diagnostic criteria will be informed of blood test results and referred to a GP. These individuals will be deemed ineligible and excluded from the study.",{"count":603,"type":23},200,"The GLOW UP study is a single-center, prospective, observational case-control study conducted in St. Gallen, Switzerland. The primary aim of the study is to examine to what degree lifestyle data collected from wearable devices and a smartphone app can identify individuals with prediabetes (vs. normoglycemic) in a real-world setting. The study also aims to characterize variability in lifestyle and glycemic patterns and to examine how between- and within-person differences relate to diabetes risk; to identify personalized predictors of early metabolic dysregulation. The study also evaluates new image-based meal tracking algorithms for predicting glycemic control and examines how reminder messages influence adherence to a \\~4-week meal logging protocol.\n\nThe study aims to enroll 200 adults aged 45 years and older with a BMI of at least 25 kg\u002Fm² and no known diagnosis of diabetes, including 100 participants with prediabetes and 100 normoglycemic (metabolically healthy) controls. Participants will be classified at the baseline visit using HbA1c and fasting plasma glucose (FPG) tests, with prediabetes defined as HbA1c 5.7-6.4% and\u002For FPG 5.6-6.9 mmol\u002FL, and normoglycemia defined as HbA1c \\\u003C5.7% and FPG \\\u003C5.6 mmol\u002FL, following clinical standards. During the \\~4-week observational period, participants will be asked to wear a smart ring, a wrist-worn smartwatch, and a blinded continuous glucose monitor (CGM). Participants will be asked to log\u002Ftake-images of their meals via a study app and to complete brief questionnaires (e.g., tracking mood, stress, and contextual meal annotations) via ecological momentary assessments. FPG and HbA1c samples will be collected at baseline to classify participants as prediabetic or normoglycemic, and again at follow-up (\\~4 weeks), which will serve as the primary outcome to evaluate associations between lifestyle and wearable-derived data and diabetes risk status.",[31],"2026-01-19",{"date":608,"type":40},"2026-01-28",{"date":610,"type":40},"2025-12-08",{"date":150,"type":23},{"name":613,"class":47},"University of St.Gallen",{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":622,"targetDuration":4,"studyType":24,"phases":624,"briefSummary":625,"conditions":626,"keywords":640,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":73},"100620350","enhancing-mental-and-physical-health-of-women-veterans-30-100620350","NCT07356479","Enhancing Mental and Physical Health of Women Veterans 3.0","Enhancing Mental and Physical Health of Women Through Engagement and Retention (EMPOWER) 3.0 (QUE 25-015)","EMPOWER","Inclusion Criteria:\n\n* This study is recruiting VA sites - not individual patients.\n* Prior to randomization, the study team will work with sites to ensure they have met the preconditions necessary to enroll in the study, which includes VISN, regional and\u002For facility level leadership support for participation.\n\nExclusion Criteria:\n\n* N\u002FA",{"count":623,"type":23},18,[26],"Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.",[627,628,629,630,631,632,633,634,635,636,637,31,638,639],"Cardiovascular Diseases","Overweight","Obesity","Hypertension","Cholesterol","Diabetes Mellitus","Prediabetic State","Menopause","Cognitive Behavioral Therapy","Primary Health Care","Stress Disorders, Post-Traumatic","Implementation Science","Quality Improvement",[641,628,629,630,631,632,633,634,635,636,637,31,642,639,643,644,645,646,647,648,649,650],"Cardiovascular diseases","Implementation science","Women","Veterans","Patient Participation","Patient Satisfaction","Patient Preference","Physicians, Primary Care","Physicians, Women","Health Behavior","2026-01-12",{"date":587,"type":40},{"date":654,"type":23},"2026-10-01",{"date":656,"type":23},"2031-09-30",{"name":658,"class":659},"VA Office of Research and Development","FED",{"id":661,"slug":662,"hasResults":12,"nctId":663,"briefTitle":664,"officialTitle":664,"acronym":4,"eligibilityCriteria":665,"healthyVolunteers":12,"sex":106,"minAge":20,"maxAge":553,"enrollmentInfo":666,"targetDuration":4,"studyType":24,"phases":668,"briefSummary":669,"conditions":670,"keywords":671,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":676,"lastUpdatePostDateStruct":677,"startDateStruct":679,"completionDateStruct":681,"leadSponsor":683,"locationsCount":73},"100612633","evaluation-of-the-effect-of-alpha-lipoic-acid-on-radiation-induced-dermatitis-in-breast-cancer-patients-100612633","NCT07256119","Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients","Inclusion Criteria:\n\n* Women aged ≥18 years.\n* Histologically confirmed invasive, early-stage breast carcinoma scheduled for adjuvant radiotherapy.\n* Receiving total radiation dose of 40 Gy for 15 sessions.\n\nExclusion Criteria:\n\n* Prior exposure to radiotherapy.\n* Inflammatory or metastatic breast carcinoma.\n* Patients with connective tissue disorders.\n* Patients with skin inflammatory diseases (e.g. ectopic dermatitis).\n* Patients with known allergy or hypersensitivity to alpha lipoic acid.\n* Concomitant use of nonsteroidal anti-inflammatory drugs, corticosteroids, or antioxidant medications.\n* Patients who will fail to sign the written consent.",{"count":667,"type":23},40,[26],"the purpose of this study is to evaluate the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients",[31],[672,673,674,675],"Radiation Induced Dermatitis","RID","Alpha Lipoic Acid","Breast Cancer","2025-12-05",{"date":678,"type":40},"2025-12-12",{"date":680,"type":40},"2024-08-06",{"date":682,"type":23},"2025-12-28",{"name":684,"class":47},"Ain Shams University",{"id":686,"slug":687,"hasResults":12,"nctId":688,"briefTitle":689,"officialTitle":689,"acronym":4,"eligibilityCriteria":690,"healthyVolunteers":18,"sex":19,"minAge":419,"maxAge":134,"enrollmentInfo":691,"targetDuration":4,"studyType":24,"phases":692,"briefSummary":693,"conditions":694,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":696,"lastUpdatePostDateStruct":697,"startDateStruct":699,"completionDateStruct":701,"leadSponsor":703,"locationsCount":216},"100465302","dialectal-behaviour-therapy-to-enhance-health-behaviour-change-for-adolescents-living-with-obesity-direction-trial-100465302","NCT05338944","Dialectal Behaviour Therapy to Enhance Health Behaviour Change for Adolescents Living With Obesity (DIRECTION Trial)","Inclusion Criteria:\n\n* 14-17 years old\n* BMI z-score \\>1.4\n* signs of mild-moderate depression (PHQ-9 score 5-19)\n* willing and able to comply with study procedures\n\nExclusion Criteria:\n\n* more than one health co-morbidity\n* being treated with medication for obesity\n* taking steroids\n* currently being treated for atypical antipsychotics\n* have an orthopedic injury or chronic illness that would prevent them from performing the intervention\n* experienced weight loss or enrolled in weight loss program in the six months prior to the study\n* they are currently and\u002For in the past 12 months have been prescribed any weight loss medication(s) including Ozempic\n* self reported history of alcoholism or drug abuse\n* history of self-harm or suicide attempts in the past 12 months\n* currently enrolled in psychotherapy or DBT\n* parents do not approve of you participating\n* unable to read, speak and understand English as translation will not be provided\n* unable\u002Funwilling to give assent\u002Fconsent",{"count":109,"type":23},[26],"This research is being conducted to evaluate emotion-focused therapy that incorporates elements of mindfulness, distress tolerance, and relationship support. The investigators want to learn if this therapy, called Dialectical Behavioral Therapy (DBT) will help improve quality of life and weight management in youth at risk for type 2 diabetes. Individuals will be randomly assigned to weekly group based session in one of 3 intervention arms; lifestyle + DBT, lifestyle alone, or a control arm.",[31,695],"Type2Diabetes","2025-10-02",{"date":698,"type":40},"2025-10-07",{"date":700,"type":40},"2023-01-14",{"date":702,"type":23},"2027-01-31",{"name":704,"class":47},"University of Manitoba"]